Neurocrit Care
February 2017
Background: Millions of patients receive vitamin K antagonist (VKA) therapy worldwide. Annually 0.2-1 % of all VKA users develops an intracranial hemorrhage (ICH).
© LitMetric 2024. All rights reserved.